Computer simulation of structured treatment interruption for HIV infection

Computer Methods and Programs in Biomedicine

Volumn 104, Issue 2, 2011, Pages 50-61

  Ferreira, Jorge ^a   Hernandez Vargas, Esteban A ^a   Middleton, Richard H ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ADVERSE OUTCOMES; CLINICAL STUDY; CLINICAL TRIAL; DRUG RESISTANCE; HIGHLY ACTIVE ANTI-RETROVIRAL THERAPIES; HIV INFECTION; IMMUNE SYSTEMS; LONG-TERM PROBLEMS; MEASUREMENT-BASED; RESISTANT MUTANTS; STRATEGIES FOR MANAGEMENTS; STRUCTURED TREATMENT INTERRUPTIONS; T CELLS; TREATMENT INTERRUPTION; WILD TYPES;

COMPUTATIONAL METHODS; COMPUTER SIMULATION; DISEASES; DYNAMIC LOADS; HEALTH RISKS; IMMUNOLOGY; MEDICAL COMPUTING; VIRUSES;

PATIENT TREATMENT;

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; VIRUS RNA;

ANTIVIRAL RESISTANCE; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL (TOPIC); COMPUTER SIMULATION; COURSE EVALUATION; DISEASE COURSE; DRUG INTERMITTENT THERAPY; DRUG RESPONSE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; MACROPHAGE; MULTIPLE CYCLE TREATMENT; STRUCTURED TREATMENT INTERRUPTION; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VIRUS IMMUNITY; VIRUS LOAD; VIRUS PARTICLE;

ANTI-HIV AGENTS; COMPUTER SIMULATION; DRUG ADMINISTRATION SCHEDULE; HIV INFECTIONS; HUMANS; VIRAL LOAD;

EID: 80054109681     PISSN: 01692607     EISSN: 18727565     Source Type: Journal    
DOI: 10.1016/j.cmpb.2011.07.011     Document Type: Article

References (41)

1. WHO, Data and Statistics: Global Summary of the Aids Epidemic, The World Health Organization, 2009, http://www.who.int/hiv/data/en/index.html.
2. C. Panel, Panel on Antiretroviral Guidelines for Adults and Adolescents, Guidelines for the use of Antiretroviral Agents in HIV-1-infected Adults and Adolescents, Department of Health and Human Services, 43-82, (December 1, 2009). http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.
3. Nowak M., Charles R. Population dynamics of immune responses to persistent viruses. Science 1996, 272:74-79.
4. Oreinstein J.M. The macropage in HIV infection. Immunobiology 2001, 204:598-602.
5. Kwon H.D. Optimal treatment strategies derived from a HIV model with drug-resistant mutants. Appl. Math. Comput. 2007, 188:1193-1204.
6. Jeffrey A.M., Xia X. Estimating the viral load response time after HIV chemotherapy. 6th IEEE Africon Conference 2002, 77-80.
7. Wodarz D. Helper-dependent vs. Helper-independent CTL responses in HIV infection-implications for drug therapy and resistance. J. Theor. Biol. 2001, 213:447-459.
8. Chun T., Stuyver L., Mizell S., Ehler L., Mican J., Baseler M., Lloyd A., Nowak M., Fauci A. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. PNAS 1997, 94:13193-13197.
9. Brian B. What did it achieve?. The 16th AIDS Conference 1998.
10. Jeffrey A.M., Xia X., Craig I.K. Structured treatment interruptions: a control mathematical approach to protocol design. Part IV: a tutorial on biomedical process control. J. Process Control 2007, 17:571-594.
11. Lisziewicz J., Rosenberg E., Lieberman J. Control of HIV despite discontinuation of antiretroviral therapy. N. Engl. J. Med. 1999, 340:1683-1684.
12. SMARTgroup M. CD4 count-guided interruption of antiretroviral treatment, the strategies for management of antiretroviral therapy (SMART) study group. NEJM 2006, 355:2283-2296.
13. Ananworanich J., Gayet A., Braz M., Prasithsirikul W., Chetchotisakd P., Kiertiburanakul S., Munsakul W., Raksakulkarn P., Tansuphasawasdikul S., Sirivichayakul S., Cavassini M., Karrer U., Genné D., Nüesch R., Vernazza P., Bernasconi E., Leduc D., Satchell C., Yerly S., Perrin L., Hill L.A., Perneger T., Phanuphak P., Furrer H., Cooper D., Ruxrungtham K., Hirschel B. CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial. Lancet 2006, 368:459-465.
14. Maggiolo F., Ripamonti D., Gregis G., Quinzan G., Callegaro A., Suter F. Effect of prolonged discontinuation of successful antiretroviral therapy on CD4+ T cells: a controlled, prospective trial. AIDS 2004, 18(3):439-446.
15. Danel C., Moh R., Minga A., Anzian A., Gomis O., Kanga C., Nzunetu G., Gabillard D., Ronet F., Sorho S., Chaix M., Eholie S., Menan H., Sauvageot D., Bissagnene E., Salomon R., Anglaret X. Trivacan ANRS 1269 trial group, CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in west Africa (Trivacan ANRS 1269 trial): a randomised trial. Lancet 2006, 367:1981-1989.
16. El-Sadr W., Neaton J. Episodic CD4-guided use of ART is inferior to continuous therapy: results of the SMART study. 13th CROI 2006.
17. Lundgren J. Progression of HIV-related disease or death (POD) in the randomized SMART study: why was the risk of POD greater in the CD4-guided (re)-initiate ART at (CD4<250cells/μl) drug conservation (DC) vs the virological suppression (VS) arm?. 13th CROI 2006.
18. El-Sadr W. Inferior clinical outcomes with episodic CD4-guided antiretroviral therapy aimed at drug conservation in SMART study: consistency of finding in all patient groups. 13th CROI 2006.
19. Cohn D. Severity and types of clinical events by proximal CD4 cell counts in the SMART study. XVI AIDS Conference 2006.
20. Burman W. The effect of episodic CD4-guided antiretroviral therapy on quality of life: results of the quality of life substudy of SMART. XVI AIDS Conference 2006.
21. Bennett S. A History of Control Engineering 1993, Peter Peregrinus, pp. 1930-1955.
22. Kalams S., Philip J., Shea K., Norman G., Trocha A., Graham S., Walker B. Levels of human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte effector and memory responses decline after suppression of viremia with highly active antiretroviral therapy. J. Virol. 1999, 73:6721-6728.
23. Davenport M. Reversibility of HIV drug resistance. Science 2000, 288(5470):1129.
24. Nathalie D., Veronique S., Gilles P., Grabar K., Nguyen S., Huyen T., Pierre G., Willy R., Dominique S. Emergence of HIV-1 mutated strains after interruption of highly active antiretroviral therapy in chronically infected patients. AIDS 2003, 17:2126-2129.
25. M. Winters, D. Cherng, K. Henry, P. Tebas, H. Valdez, M. Wantman, D. Katzenstein, Emergence of drug resistance mutations during treatment interruption in patients with undetectable viral loads, in: XIV International HIV drug resistance workshop, Quebec-Canada, Antivir Ther. 10 (Suppl. 1) (2005) S37 (abstract no. 35).
26. Ananworanich J., Nuesch R., Chetchotisakd P., Vibhagool A., Wicharuk S., Ruxrungtham K., Furrer H., Cooper D., Hirschel B., Bernasconni E., Cavassini M., Fegard C., Genne D., Khanna N., Perrin L., Phanupak P., Ubolyam S., Vernazza P., Yerly S. Swiss Cohort Study, failures of 1 week on, 1 week off antiretroviral therapies in a randomized trial. AIDS 2003, 17:F33-F37.
27. Philips A., Miller V., Lepri A., Klauke S., Bickel M. Durability of HIV-1 viral suppression over 3.3 years with multi-drug antiretroviral therapy in previously drug-naive individuals. AIDS 2001, 15:2379-2384.
28. Fischer M., Hafner R., Schneider C., Trkola A., Joos B. HIV RNA rebounds within days during structured treatment interruptions. AIDS 2003, 17:193-197.
29. Dybul M. Short-cycle structured intermittent treatment of chronic HIV infection with highly active antiretroviral therapy: effects on virologic, immunologic and toxicity parameters. PNAS 2001, 98:15161-15166.
30. Ruiz L., Martinez J., Romeu J., Paredes R., Zayat M., Marfil S., Negredo E., Sirera G., Tural C., Clotet B. Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression. AIDS 2000, 14:397-403.
31. Rosenberg E., Altfeld M., Poon S., Phillips N., Wilkes B., Eldridge R., Robbins G., Aquila R., Goulder P., Walker B. Immune control of HIV-1 after early treatment of acute infection. Nature 2000, 407:523-526.
32. C. Katlama, S. Domingues, C. Duvivier, C. Delaugerre, G. Peytavin, M. Legrand, V. Calvez, K. Goulairn, D. Costagliola, The 10th Conference on retrovirus and opportunistic infections, Toronto, Canada, 2003 (abstract 68).
33. Ortiz G. Structure antiretroviral treatment interruptions in chronically HIV-1-infected subjects. PNAS 2001, 98:13288-13293.
34. Hatano H., Vogel S., Yoder C., Metcalf J., Dewar R., Davey R., Polis M. Pre-HAART HIV burden approximates post-HAART viral levels following interruption of therapy in patients with sustained viral suppression. AIDS 2000, 14:1357-1363.
35. Neumann A., Tubiana R., Calvez V., Robert C., Li T., Agut H., Autran B., Katlama C., Comet-study-group G. HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment. AIDS 2002, 13:677-683.
36. Papasavvas E., Grant R., Sun J., Mackiewicz A., Pistilli M., Gallo C., Kostman J., Mounzer K., Shull J., Montaner L. Lack of persistent drug-resistant mutations evaluated within and between treatment interruptions in chronically HIV-1-infected patients. AIDS 2003, 17:2337-2343.
37. Davey R. A cytostatic drug improves control of HIV-1 during structure treatment interruptions: a randomized study. PNAS 1999, 96:15109-15114.
38. Fagard C. A prospective trial of structured treatment interruptions in human immunodeficiency virus infection. Arch. Intern. Med 2003, 163:1220-1226.
39. Fisher M., Hafner R., Schenider C., Trkola A., Joos B., Joller H., Hisrchel B., Weber R., Gunthard H. HIV RNA in plasma rebounds within days during structured treatment interruption. AIDS 2002, 17:195-199.
40. M. Dybul, A randomized, controlled trial of long cycle structured intermittent versus continuous ARV therapy for chronic HIV infection, in: The 10th Conference on Retroviruses and Opportunistic Diseases, 2003 (abstract 681-b).
41. Pouton M., Sabine C., Fisher M. Immunological changes during treatment interruptions: risk factors and clinical sequeale. AIDS 2003, 17:126-128.